John F. Manzello

Promosome LLC is a biotechnology company specializing in technologies related to the regulation of protein synthesis through translation initiation. Its proprietary mRNA engineering technology exploits features of the natural translation process in both prokaryotic and eukaryotic cells. The technologies involve recoding mRNAs for biotherapeutic agents to enhance ribosome recruitment, eliminate false starts in translation initiation, and ensure message stability in both eukaryotic and prokaryotic cells. Promosome was founded by William J. Gedale and John R. Costantino in 2003 and is headquartered in New York, NY.

Part of Charles River Laboratories International, Inc., Primedica Corp develops and produces pharmaceutical products for the biopharmaceutical industry. The company is based in Worcester, MA. Primedica was acquired by Charles River Laboratories, Inc. from rEVO Biologics, Inc. on February 27, 2001 for $42.50 million.

Ajinomoto Althea, Inc. provides biopharmaceutical contract development and manufacturing services to biotechnology and pharmaceutical companies worldwide. It offers development services in the areas of process development, protein formulation technology, analytical development and validation, and regulatory support. The company was founded by Magda Marquet and Francois Ferre in 1998 and is headquartered in San Diego, CA.

Cohesive Technologies, Inc. designs, manufactures, and markets liquid chromatography solutions. It serves to the drug discovery, pharmaceutical, contract research, and clinical diagnostic industries. The company was founded in 1991 and is headquartered in Franklin, MA.

Recopharma AB is a biotechnology company that develops ophthalmic products based on protein-carbohydrate interactions. It develops a technology that uses mucins, naturally occurring proteins produced by epithelial tissues with many potential applications. The company was founded in 2004 and is headquartered in Huddinge, Sweden

rEVO Biologics, Inc. engages in the development and commercialization of specialty therapeutics to address unmet medical needs in patients with rare, life-threatening conditions. Its products include ATryn, which prevents blood clots during and after surgery and childbirth for patients with hereditary antithrombin deficiency. The company was founded in February 1993 and is headquartered in Framingham, MA.

Abzena Ltd. engages in the provision of proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products. It offers antibody discover and candidate screening, immunology and immunogenicity assessment, antibody and protein engineering, bio conjugation, custom synthesis of cytotoxic payloads, reagents, and other small molecules, manufacture of payload linkers, development of manufacturing cell lines, and manufacture of biopharmaceuticals. The company was founded by Sunil Shaunak in 2001 and is headquartered in Cambridge, the United Kingdom.